Thomas Clozel

Thomas Clozel

About

Detail

CEO and Co-founder
New York, United States

Timeline

work
Job
school
Education
folder
Project
auto_stories
Publication

Résumé

Jobs verified_user 0% verified
  • EQT Group
    Advisor
    EQT Group
    Jan 2025 - Current (1 year 10 months)
  • Septhom
    Co-fondateur and Executive Chairman
    Septhom
    Jan 2025 - Current (1 year 10 months)
  • Xprize
    Brain trust
    Xprize
    Jun 2024 - Current (2 years 5 months)
  • Université ParisSaclay
    Member Board of Directors
    Université ParisSaclay
    Apr 2024 - Current (2 years 7 months)
  • Université ParisSaclay
    Member Board of Directors
    Université ParisSaclay
    Apr 2024 - Current (2 years 7 months)
  • Cure
    Non operational cofounder
    Cure
    Mar 2024 - Current (2 years 8 months)
  • Bioptimus
    Non operational cofounder and Board Dlrector
    Bioptimus
    Feb 2024 - Current (2 years 9 months)
  • Bioptimus
    Non operational cofounder
    Bioptimus
    Feb 2024 - Current (2 years 9 months)
  • Fragment YC S
    Seed Investor
    Fragment YC S
    Nov 2023 - Dec 2023 (2 months)
  • Osium AI YC S
    Seed Investor
    Osium AI YC S
    Oct 2023 - Nov 2023 (2 months)
  • The Health Network
    Global expert
    The Health Network
    May 2023
    Pro bono advisory to Israeli health tech scene
  • Grace
    Advisor
    Grace
    Mar 2023 - Current (3 years 8 months)
  • Sofinnova Partners
    Venture advisor
    Sofinnova Partners
    Aug 2022 - Current (4 years 3 months)
  • Kanji
    Seed Investor
    Kanji
    Apr 2022
  • Dioxycle
    Investor
    Dioxycle
    Jan 2022 - Sep 2022 (9 months)
  • Mindmesh YC S
    Seed Investor
    Mindmesh YC S
    Jun 2021
  • Resilience Care
    Seed Investor
    Resilience Care
    Feb 2021
  • Patch Biosciences
    Seed Investor
    Patch Biosciences
    Aug 2020 - Sep 2020 (2 months)
  • Owkin
    Chief Executive Officer and Co-founder
    Owkin
    Jun 2016 - Current (10 years 5 months)
    Artificial Intelligence to enable breakthrough medical moments in medicine
    www.owkin.com

    OWKIN is developing the reference federated platform on patients data to improve precision medicine from phase 1 to bedside.

    Our team is international, multidisciplinary with incredible talent in machine learning, medicine and business. Our data scientists are among the best in the world, with several Kaggle Masters (top global 100), a DREAM Challenge top performer, and publications in ICML, NIPS and other top scientific journals.

    OWKIN develops scientific collaborations with top-tier medical institutions and partners with
  • Owkin
    CEO and Co-founder
    Owkin
    Jun 2016 - Current (10 years 5 months)
    Artificial Intelligence to enable breakthrough medical moments in medicine
    www.owkin.com

    OWKIN is developing the reference federated platform on patients data to improve precision medicine from phase 1 to bedside.

    Our team is international, multidisciplinary with incredible talent in machine learning, medicine and business. Our data scientists are among the best in the world, with several Kaggle Masters (top global 100), a DREAM Challenge top performer, and publications in ICML, NIPS and other top scientific journals.

    OWKIN develops scientific collaborations with top-tier medical institutions and partners with
  • Owkin
    Chief Biology ASI Officer and Co-founder
    Owkin
    Jun 2016 - Current (10 years 5 months)
    Artificial Intelligence to enable breakthrough medical moments in medicine
    www.owkin.com

    OWKIN is developing the reference federated platform on patients data to improve precision medicine from phase 1 to bedside.

    Our team is international, multidisciplinary with incredible talent in machine learning, medicine and business. Our data scientists are among the best in the world, with several Kaggle Masters (top global 100), a DREAM Challenge top performer, and publications in ICML, NIPS and other top scientific journals.

    OWKIN develops scientific collaborations with top-tier medical institutions and partners with
  • C
    Clinical Assistant Professor
    CHU Henri Mondor de Créteil
    Nov 2012 - Nov 2014 (2 years 1 month)
  • Weill Cornell Medicine
    Research Fellow
    Weill Cornell Medicine
    Nov 2009 - Sep 2012 (2 years 11 months)
    Hematology/Oncology department

    Ari Melnick's lab
    Especially work on epigenetic treatments in agressive lymphomas as HDAC or DNMT inhibitors

    Collaborations:
    Memorial Sloan Kettering/Metastatic breast cancer Dr Choisis
    Weill Cornell/ Bladder cancer Dr Shariat
  • Université Paris Cité
    Master 2 parcours recherche
    Université Paris Cité
    Sep 2009 - Jun 2010 (10 months)
    Optimization and rationalization on chemosensitization of DLBCL cell lines by epigenetic treatments such as DNMT inhibitors or HDAC inhibitors
  • Greater Paris University Hospitals APHP
    Internat
    Greater Paris University Hospitals APHP
    Jan 2006 - Dec 2012 (7 years)
    Clinical Hematology
    Internal Medecine
    Public Health
  • The Mount Sinai Hospital
    Rotation resident
    The Mount Sinai Hospital
    Jul 2004 - Dec 2005 (1 year 6 months)
    Rotation in Neurology
    Movement Disorders unit
    Work with Dr.Jean-Michel Gracies
Education verified_user 0% verified
  • Joan Sanford I Weill Medical College of Cornell University
    research fellowship, Hematology-oncology
    Joan Sanford I Weill Medical College of Cornell University
    Jan 2009 - Dec 2011 (3 years)
  • W
    research fellowship, Hematology-oncology
    Weill Medical College of Cornell University
    Jan 2009 - Dec 2011 (3 years)
  • Icahn school of medicine at mount sinai
    Clinical rotation, Neurology Department
    Icahn school of medicine at mount sinai
    Jan 2006 - Dec 2006 (1 year)
Projects (professional or personal) verified_user 0% verified
    Publications verified_user 0% verified
    • B
      Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose ther
      British Journal of Hematology
      Sep 2013
    • C
      Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma
      Cancer Discovery
      Sep 2013
      The problem of chemoresistant DLBCL remains the most urgent challenge in the clinical management of patients with this disease. We describe a mechanism-based approach toward the rational translation of DNMTIs for the treatment of high-risk DLBCL.
    • B
      Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-uret
      BJU Int
      Aug 2013
    • A
      Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy.
      Ann Surg Oncol
      Mar 2013
    • L
      Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
      Leukemia
      Oct 2012
    • E
      Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment
      Eur Urol
      Feb 2012
    • E
      Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial
      Eur Urol
      Jan 2012
    • B
      DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation
      Blood
      Sep 2011
    • J
      Age-dependent Mendelian predisposition to herpes simplex virus type 1 encephalitis in childhood
      J Pediatr
      Oct 2010
    • H
      Slow relapse in acute myeloid leukemia with inv(16) or t(16;16)
      Haematologica
      Oct 2009
    This is a community-created genome.